Overview: HHV-8 IgG TestIntroduction: The HHV-8 IgG Test detects HHV-8 IgG antibodies to diagnose past infection with human herpesvirus 8, linked to Kaposi's sarcoma or lymphoma, helping guide cancer treatment. Affecting 1 in 10,000 people in endemic areas, HHV-8 poses diagnostic challenges due to latent infection. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses ELISA for high sensitivity, supporting virology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in oncology.
Other Names: HHV-8 Antibody Test, Kaposi's Sarcoma Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: HHV-8 serology began in the 1990s with research by Chang, who identified the virus. ELISA advancements in the 2000s by Thermo Fisher improved detection, surpassing earlier immunofluorescence methods.
Purpose: Detects HHV-8 IgG antibodies to diagnose past infection, guides cancer therapy, and evaluates patients with skin lesions, aiming to manage disease.
Test Parameters: HHV-8 IgG antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of cancer or skin lesions.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document skin lesions or cancer history. Include current medications or immune status.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., lymphoma), and sample collection risks.
Procedural Considerations: Uses ELISA to measure IgG, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive IgG confirms past infection, guiding therapy. Early treatment might prevent progression, while untreated cases lead to cancer. Normal levels may require PCR.
Specialist Consultation: Consult an oncologist or infectious disease specialist for interpretation.
Additional Supporting Tests: HHV-8 PCR, biopsy, or imaging to confirm diagnosis.
Test Limitations: Indicates past infection only; correlation with symptoms needed. False positives possible with cross-reactivity.
References: CDC Guidelines, 2023; New England Journal of Medicine, Chang Y, 2022.
